Drugs that inhibit HIF2, and HIF-responsive gene products such as VEGF, are now cornerstones of kidney cancer therapy, while HIF agonists, which block oxygen-dependent prolyl hydroxylation of the HIFα subunits, appear promising for the treatment of anemia and ischemia. Here, VEGFA is linked to anemia (phenotype).